ホモアルギニン,心血管疾患リスク,死亡率
Winfried März1, Andreas Meinitzer, Christiane Drechsler
1Clinical Institute of Medical and Chemical Laboratory Diagnostics, Division of Endocrinology and Nuclear Medicine, Medical University of Graz, Graz, Austria.
Circulation
|August 25, 2010
まとめ
低ホモアルギニンのレベルは,冠動脈血管検査と血液透析を受ける患者の心血管疾患の増加と全死亡率に関連しています. これは,心臓血管リスクの潜在的なバイオマーカーとしてホモアルギニンを強調しています.
科学分野:
- 心血管医学 心血管医学
- バイオケミストリー バイオケミストリー
- ネフロロジーはネフロロジーを用います.
背景:
- アミノ酸誘導体であるホモアルギニンは,酸化窒素の可用性と内皮機能に影響を与える可能性があります.
- ホモアルギニンのレベルが心血管疾患と死亡率に与える影響は,依然としてほとんど不明である.
研究 の 目的:
- ホモアルギニン濃度と心血管疾患およびあらゆる原因による死亡率との関連を調査する.
- ホモアルギニン,腎機能,内皮機能不全マーカーの関係を探求する.
主な方法:
- 2つのコホートにおけるホモアルギニン濃度に基づく死亡リスクの評価:LURIC研究 (冠動脈血管撮影) の患者3,305人,4D研究 (血液透析) の患者1,244人.
- 分析された関連性は,推定される球の濾過率と粘着分子 (ICAM-1,VCAM-1) と関連しています.
主要な成果:
- LURIC研究では,ホモアルギニンの最低四分位数 (<1.85μmol/L) は,最高四分位数 (>3.1μmol/L) と比較して,心臓血管疾患による死亡率が4倍以上高いことを示しました.
- ホモアルギニンの低レベルは腎機能障害と相関し,内皮機能不全マーカーのレベルは高かった.
- 平均ホモアルギニン濃度 (<0.87μmol/L) が低い血液透析患者 (4D研究) は,より高い濃度 (>1.4μmol/L) を有する患者と比較して死亡リスクが2倍に増加しました.
結論:
- ホモアルギニンのレベルは,冠動脈動脈検査と血液透析を受けている患者の心血管疾患および全因死亡率と独立して関連しています.
- ホモアルギニンを死亡率と結びつける根本的なメカニズムを理解するために,さらなる研究が必要です.
関連する概念動画
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Antianginal Drugs: Nitrates and β-Blockers
1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
769
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
769
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Heart Failure V: Medical Management
642
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
642
Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747


